Lidoflazine and Propranolol Combination Treatment in Chronic Stable Angina

Charlap, Shlomo; Kimmel, Bruce; Berezow, Joel; Molinas, Sharon; Strom, Joel; Wexler, John; Willens, Howard; Klein, Neal; Pollack, Simcha; Frishman, William H.
April 1985
Angiology;Apr1985, Vol. 36 Issue 4, p240
Academic Journal
The short-term (1 month) and long-term (6 months) safety of combination lidoflazine-propranolol therapy was investigated in an open trial of 15 patients with stable angina of effort. The possible advantages of adding lidoflazine (titrated to 360 mg daily) to patients having a therapeutic response to propranolol (80-400 mg daily) was also evaluated. Effects on non-invasive indexes of left ventricular function (echocardiography, systolic time intervals, radionuclide ventriculography) and exercise tolerance (treadmill exercise testing) were deter- mined. There was no change in mean resting heart rate with the combination therapy, although one patient developed sinus bradycardia at a rate of 44 and had to have his propranolol dose reduced. Electrocardiographic analysis showed significant prolongation of the QT, intervals on lidoflazine-propranolol therapy compared to propranolol alone, with 3 patients having QT, interval prolongation to above .53 seconds, but there was no evidence of increased arrhythmogenesis with the combination therapy compared to propranolol alone, Left ventricular end-diastolic volume index tended to rise with combination therapy. However, lidoflazine-propranolol therapy did not produce any significant effects on resting ejection fraction determined by Memode echocardiography or by radionuclide ventriculography. Radionuclide ventriculography determined peak exercise ejection fractions were also not significantly changed with combination therapy compared to propranolol alone. There were only small, insignificant improvements in exercise tolerance with the tidoflazine-propranolol combination treatment compared to propranolol alone. It is concluded that lidoflazine-propranolol combination therapy is generally safe but has the potential of causing serious adverse effects in certain patients, i.e. those with sick sinus disease, prolonged QT, intervals, and severe baseline left ventricular dysfunction, and that caution must be exercised in its use. Furthermore, it would appear that combination therapy provides only slight, if any, improvements in exercise tolerance in patients with chronic stable angina having a therapeutic response to oral propranolol.


Related Articles

  • Capecitabine.  // Reactions Weekly;10/2/2010, Issue 1321, p12 

    The article describes the case of a 77-year-old woman who took capecitabine for sigmoid andenocarcinoma and later experienced Prinzmetal's angina.

  • 755 Combined ultrasound and ECG selection criteria increase the proportion of responders to cardiac resynchronization therapy. Pontillo, D.; Achilli, A.; Sassara, M.; Turreni, F.; Rossi, P.; Achilli, P.; Carluccio, E.; Ambrosio, G. // European Journal of Heart Failure. Supplements; 

    An abstract of the study "Combined Ultrasound and ECG Selection Criteria Increase the Proportion of Responders to Cardiac Resynchronization Therapy," by D. Pontillo and colleagues is presented.

  • cardiotherapy.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p370 

    A definition of the term "cardiotherapy" which refers to the treatment of heart diseases is presented.

  • The `Berlin Heart' assist device. Drews, Thorsen; Loebe, Matthias; Hennig, Ewald; Kaufmann, Friedrich; Muller, Johannes; Hetzer, Roland // Perfusion;Jul2000, Vol. 15 Issue 4, p387 

    Evaluates the Berlin Heart assist device. System description and implantation; Experience with the device at the Deutsches Herzzentrum Berlin.

  • Treat complete heart risk.  // Clinical Advisor;Mar2010, Vol. 13 Issue 3, p14 

    The article discusses the effectiveness of tailoring treatment for patients with heart diseases.

  • Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. Smeeth, Liam; Haines, Andy; Ebrahim, Shah // BMJ: British Medical Journal (International Edition);06/05/99, Vol. 318 Issue 7197, p1548 

    Presents a study which examined pooled numbers needed to treat derived from trials and meta-analyses of interventions to prevent cardiovascular disease. Effects of treatment with statins; Effects of variation in baseline risk; Implication of clinical setting; Details on the findings of the...

  • NOW AVAILABLE.  // Drug Topics;4/17/2006, Vol. 150 Issue 8, p66 

    The article announces the availability of a partial fatty acid oxidation inhibitor, Ranexa (ranolazine extended-release tablets), a medicine that treats chronic angina from Palo Alto, California-based CV Therapeutics. The drug comes in 500-mg strength and is said to prolong the QT interval and...

  • Barriers to referral in patients with angina: qualitative study. Gradner, Katy; Chapple, Alison // BMJ: British Medical Journal (International Edition);08/14/99, Vol. 319 Issue 7207, p418 

    Details a study which explored barriers to patients being referred for possible revascularization. Participants and methods of the study; Fear of hospitals, operations and medical tests; Angina as a chronic illness to be managed or denied; Patients' perception of age and its effect on...

  • Personal View. Ross, Alistair // British Medical Journal (Clinical Research Edition);11/7/1987, Vol. 295 Issue 6607, p1204 

    Relates experiences on the occurrence of mild coronary thrombosis in Great Britain. Use of thrombolytic agent for the treatment of mild coronary thrombosis; Installment of electrocardiography; Importance of a medical consultation in the occurrence of vague chest pains and dyspepsia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics